Sample review packet for one flagged approved claim.
Reference: NC-2026-001-AD
This is the item-level output inside the ranked re-review list: one claim, one source record, one decision to make.
What the review packet contains
Each review packet shows the affected approved claim, use context supplied by the customer, what changed, why the claim was prioritized, the decision the reviewer needs to make, and what remains outside NC's authority. Private packets include more detail and the full evidence trail.
Current coverage restrictions remain justified
Coverage owner asks whether the prior restriction can still be relied on for a defined patient-selection and safety-review context.
The public record shows available evidence has not yet changed enough to support broader routine coverage. The current decision is whether to keep coverage within tightly defined patient-selection, biomarker-confirmation, and safety-review criteria. The evidence supports slowing of cognitive decline in this population with established safety-review requirements.
The evidence supports the claim, but with specific caveats attached: the restriction may narrow to biomarker-confirmed subgroups as real-world safety data accumulates. The institution chooses and records the final decision. Key caveats: Qualify the evidence statement to apply strictly to biomarker-confirmed early Alzheimer's disease matching the trial inclusion criteria, and keep ARIA safety review requirements explicit.
Every finding traces to a specific source event in the public record. Conditions that would justify another review: Publication of updated multi-society clinical practice guidelines; FDA safety labeling revision regarding ARIA review frequency.
This public example uses illustrative language. A private review packet starts with your approved claim and use context, then returns named source events, what changed, what still holds, the decision to make, and the conditions for another review.
Method basis
Methods reflected in this sample.
The sample applies established approaches to evidence appraisal, transparent reporting, formulary evidence organization, and real-world evidence review without owning the final disposition.
- GRADE Evidence to Decision frameworks: a systematic and transparent approach to making well informed healthcare choices
Shows why evidence assessment and final decisions should be structured separately.
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Supports transparent reporting of search, selection, appraisal, synthesis, and update methods.
- AMCP Format for Formulary Submissions
Shows how healthcare decision makers expect clinical and economic evidence to be organized for formulary, coverage, policy, and reimbursement review.
- Good practices for real-world data studies of treatment and/or comparative effectiveness
Frames real-world evidence around reproducibility, registration, stakeholder involvement, and decision-maker confidence.
Submit an approved claim and use context for a fit check.
No charge, no commitment. We confirm whether it fits the re-review framework.